Full video transcriptClick to expand
Auto-generated transcript of @primal_health_wellness's video. Quoted here for educational fact-check commentary; original creator retains all rights to the video content.
- 0:00Be careful. Everyone's getting pregnant with the zenphic babies.
- 0:04Numerous clients are reporting pregnancies while on GLP1s and GIP therapies.
- 0:10So why is this happening now?
- 0:12It's happening for a few reasons. One that you'd expect and one that kind of came out of nowhere.
- 0:17We've all heard time and time again how GLP1s is a gastric emptying delay drug.
- 0:22Keeping food in your stomach longer, helping the absorption with insulin and glucose to your system.
- 0:27But also with that gastric emptying delay drug comes the
- 0:31Ineffectiveness or the effect of the absorption rate or the absorption issues with other drugs and food.
- 0:37Considering like Tylenol or other over-the-counter medications as well as oral contraceptives.
- 0:42Did you know that during your screening for your GLP1 therapies that you should have been asked if there was a risk of becoming
- 0:48pregnant, getting pregnant or even breastfeeding?
- 0:51Well, there's many studies coming out showing the effectiveness or the
- 0:56Ineffectiveness with these oral contraceptives with GLP1 therapy. So by reduced absorption
- 1:01With the gastric emptying delay drug this shows the ineffectiveness of an oral contraceptive.
- 1:07So make sure you have a backup plan if you are on this medication.
- 1:10The other reason you might not expect and really isn't about an infertility issue. It's about insulin resistance, cortisol,
- 1:17PCOS and morbid obesity. These clients begin their GLP1 therapies, lose weight, feel balanced and understand that it's just more about
- 1:26Not only the weight loss but the hormone will imbalance. When you're dealing with that A1c control and that starts
- 1:33Declining then you start decreasing or depleting that cortisol and increasing your chance of becoming pregnant.
- 1:40Did you yourself become pregnant while using GLP1 therapy or have any other family members or friends become pregnant?
- 1:46Please comment below looking forward to hearing from you.
Do GLP-1 drugs really make birth control fail and cause surprise pregnancies?
Quick answer
Women initiating GLP-1 receptor agonist therapy who rely on oral contraceptives should be counseled about using a backup contraceptive method during dose escalation, per prescribing guidance, though pharmacokinetic data does not confirm meaningful reductions in total oral contraceptive exposure. Separately, women with PCOS or obesity-related anovulation may experience restored ovulatory function as a secondary effect of GLP-1-driven weight loss and insulin sensitization, representing a distinct and clinically important fertility pathway. Both mechanisms warrant proactive reproductive planning discussions before and during GLP-1 therapy initiation.
Video review standard
Clinical fact-check snapshot
FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.
Evidence signal
Source-backed review
Regulatory reality
Compounded Semaglutide access requires the right clinical path
Safety screen
Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.
This page currently connects to 8 source-backed evidence items through visible references or structured citation data.
PubMed evidence trail
Research sources used to frame this page
For Do GLP-1 drugs really make birth control fail and cause surprise pregnancies?, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Primary STEP 1 trial source for semaglutide weight-management efficacy and adverse-event context.
PubMed
Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance
Used for maintenance, discontinuation, and weight-regain discussions after semaglutide response.
PubMed
Tirzepatide Once Weekly for the Treatment of Obesity
Primary SURMOUNT-1 trial source for tirzepatide weight-loss ranges and tolerability.
PubMed
Continued Treatment With Tirzepatide for Maintenance of Weight Reduction
Used for continuation, stopping, and maintenance questions after initial weight loss.
PubMed
Provider decision path
Use local research to choose a safer review path
Direct answer
Compounded Semaglutide is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.
Evidence check
Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.
Safety check
Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.
Next step
When you are ready, the get-started flow can collect the details needed for a prescription review instead of leaving you to guess.
Claim path
Keep researching this semaglutide video claims cluster
Best for searchers comparing social semaglutide claims with GLP-1 eligibility, outcomes, and safety context.
Page-specific review note
What this exact clip is really saying
This FormBlends review is specific to "Do GLP-1 drugs really make birth control fail and cause surprise pregnancies?" from Primal Health + Wellness. We read the clip as a GLP-1 social video fact-checks claim about Compounded Semaglutide, then separate the useful signal from what a short social video cannot prove. The page-specific claim focus is: Women initiating GLP-1 receptor agonist therapy who rely on oral contraceptives should be counseled about using a backup contraceptive method during dose escalation, per prescribing guidance, though pharmacokinetic data does not confirm meaningful reductions in total oral contraceptive exposure.
The reason this review is not generic is the source wording and the canonical claim label "glp1 did you know the ineffectiveness of oral contraceptives on w." In this clip, the useful excerpt is: "Be careful." That wording changes the review because it points to Compounded Semaglutide safety, access, evidence, and fit, not a one-size-fits-all protocol.
The source trail for this page is checked against Once-Weekly Semaglutide in Adults with Overweight or Obesity (2021), Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance (2021), and Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight (2022), plus the creator's own wording. Compounded Semaglutide still needs an eligibility review, medication-interaction screen, access check, and quality-control review before anyone treats a social clip as medical advice.
Claim verdict
The useful answer behind this video
This page is built to answer the specific claim behind the clip, then separate what is useful from what still needs clinical context. That makes the URL more than a repost: it gives Google, readers, and AI retrieval systems a concise verdict with source and safety boundaries.
Claim being checked
Women initiating GLP-1 receptor agonist therapy who rely on oral contraceptives should be counseled about using a backup contraceptive method during dose escalation, per prescribing guidance, though pharmacokinetic data does not confirm meaningful reductions in total oral contraceptive exposure.
FormBlends verdict
Compounded Semaglutide safety, access, evidence, and fit
Evidence strength
Source-backed review with clinical or regulatory citations.
Patient-safe next step
Compare the claim with the Compounded Semaglutide guide, safety notes, access rules, and a licensed-provider review.
What to do with this video
Use the clip as a claim to verify, not a treatment plan
What it helps with
- Women initiating GLP-1 receptor agonist therapy who rely on oral contraceptives should be counseled about using a backup contraceptive method during dose escalation, per prescribing guidance, though pharmacokinetic data does not confirm meaningful reductions in total oral contraceptive exposure. Separately, women with PCOS or obesity-related anovulation may experience restored ovulatory function as a secondary effect of GLP-1-driven weight loss and insulin sensitization, representing a distinct and clinically important fertility pathway. Both mechanisms warrant proactive reproductive planning discussions before and during GLP-1 therapy initiation.
- FDA prescribing information for semaglutide recommends using a non-oral or backup contraceptive method, particularly during the first four weeks of therapy or dose escalation.
- A 2023 pharmacokinetic analysis (Hausner et al., Clinical Pharmacokinetics) found semaglutide reduced peak concentration of oral contraceptive hormones but did not significantly alter total drug exposure, meaning the pill-failure mechanism is not as clear-cut as the video implies.
What it may miss
- It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
- Compounded Semaglutide decisions still need source quality, legal access, and provider oversight checks.
- Social video captions rarely show the full evidence base behind a claim.
Best next step
Compare the claim against the Compounded Semaglutide guide, cost path, safety notes, and provider review before acting.
Review Compounded SemaglutideWhat You'll Learn
- FDA prescribing information for semaglutide recommends using a non-oral or backup contraceptive method, particularly during the first four weeks of therapy or dose escalation.
- A 2023 pharmacokinetic analysis (Hausner et al., Clinical Pharmacokinetics) found semaglutide reduced peak concentration of oral contraceptive hormones but did not significantly alter total drug exposure, meaning the pill-failure mechanism is not as clear-cut as the video implies.
- Women with PCOS who had irregular or absent cycles due to obesity or insulin resistance may see ovulatory function return during GLP-1 therapy, a fertility change that can occur before significant weight loss is visible.
- Both semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) are not recommended for use during pregnancy based on animal reproductive toxicity data, and should be discontinued before planned conception.
- The cortisol-depletion explanation offered in the video does not reflect established endocrinology and should not be used to understand or explain GLP-1-related fertility changes.
- Reproductive planning, including contraceptive method review and fertility counseling, should be part of any GLP-1 therapy intake for women of childbearing age, regardless of prior infertility history.
Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team · This is not a transcript. It is our independent review of the video above.
What did @primal_health_wellness actually say?
The creator made two core arguments. First, that GLP-1 medications cause "ineffectiveness" of oral contraceptives by slowing gastric emptying, reducing pill absorption, and leading to unintended pregnancies. Second, that GLP-1 drugs restore fertility indirectly by improving insulin resistance, reducing cortisol, and resolving PCOS-related hormonal dysfunction. They encouraged followers to share pregnancy stories in the comments, framing this as an emerging pattern across their client base.
The creator also claimed that providers "should have been asked" about pregnancy risk during GLP-1 screening, implying this is a standard but frequently missed step. Both arguments carry real kernels of truth, but the way they were stitched together overstates the evidence and misrepresents the mechanism behind at least one of those claims.
Does the science back this up?
Partially, but the gastric emptying argument is weaker than the creator implies. The FDA-approved labeling for semaglutide does note that it slows gastric emptying, which could theoretically reduce the absorption rate of co-administered oral medications. However, the clinical data on oral contraceptives specifically is thin.
A pharmacokinetic substudy in the SUSTAIN trial program (Hausner et al., 2023, Clinical Pharmacokinetics) found that semaglutide caused modest reductions in the Cmax of ethinyl estradiol and levonorgestrel, but AUC values, the metric that actually reflects total drug exposure and efficacy, were not significantly affected. The European Medicines Agency reviewed this and concluded that oral contraceptive efficacy was not meaningfully compromised. That is not the same as saying there is zero risk. It means the mechanism the creator describes does not translate cleanly into documented contraceptive failure at the clinical level.
The fertility restoration argument is better supported. Multiple observational studies, including work by Palomba et al. (2021, Human Reproduction Update), confirm that weight loss and improved insulin sensitivity in women with PCOS can restore ovulatory cycles that had been suppressed by metabolic dysfunction. GLP-1 drugs that drive that weight loss could plausibly mediate the same effect.
What did they get wrong (or right)?
The creator gets credit for flagging the PCOS and insulin resistance angle. That part is grounded in real endocrinology. Women with PCOS who were previously anovulatory due to obesity or insulin resistance can become unexpectedly fertile as metabolic markers improve, and this is a legitimate clinical concern that deserves more airtime.
Where they go wrong is on the cortisol claim. The statement that improving A1c control causes "decreasing or depleting that cortisol" is not physiologically accurate as described. Cortisol and A1c do interact, chronic hypercortisolism worsens insulin resistance, but normalizing glucose does not simply "deplete" cortisol. The mechanism is more complex and the creator's version of it is garbled enough to be misleading.
The framing that GLP-1 drugs are a "gastric emptying delay drug" as their primary identity is also reductive. These are receptor agonists with systemic metabolic, appetite, and neurological effects. Reducing them to one mechanism understates how they work and makes the contraceptive interaction sound more straightforward than it is.
The anecdote-as-evidence approach, citing "numerous clients" and asking followers to confirm with their own pregnancy stories, is the most troubling element. That is not how you establish a drug interaction signal. It is how you build a compelling TikTok.
What should you actually know?
If you are on a GLP-1 medication and relying on oral contraceptives, the most evidence-based recommendation from prescribing guidelines is to use a non-oral backup method, such as a condom or patch, for at least four weeks after starting or escalating your GLP-1 dose. This is a precautionary recommendation, not a confirmation that pills stop working entirely.
The fertility restoration pathway is real and underappreciated. If you have PCOS, a history of irregular cycles, or were told pregnancy was unlikely due to metabolic factors, starting a GLP-1 medication could change that picture faster than you expect. This is something to discuss with your prescriber before starting therapy, not after a missed period.
GLP-1 drugs are not approved for use during pregnancy. Both semaglutide and tirzepatide carry guidance recommending discontinuation before conception and are not recommended during pregnancy based on animal studies showing fetal harm. If you are pregnant or planning to become pregnant, that conversation with your provider cannot wait.
Bottom line
This video raises a legitimate public health issue but packages it with shaky mechanistic claims and zero citations. The "Ozempic baby" concern is real enough that the FDA label addresses it. But the creator's explanation of why it happens, especially the cortisol claim and the overstated contraceptive failure mechanism, does not hold up to scrutiny. Use this as a starting point for a conversation with your provider, not as clinical guidance.
Interested in GLP-1 or peptide therapy?
Get matched with licensed-provider review to help decide if it is right for you.
About the Creator
Primal Health + Wellness · TikTok creator
3.6K views on this video
Did you know the ineffectiveness of oral contraceptives on weight loss medications leading to Ozempic Babies? #pregnancy #weightloss #pcos #infertility #greenscreenvideo
Frequently asked questions
Quick answers based on this video and our medical team review.
What does the video say about fda prescribing information for semaglutide recommends using a non-oral?
FDA prescribing information for semaglutide recommends using a non-oral or backup contraceptive method, particularly during the first four weeks of therapy or dose escalation.
What does the video say about a 2023 pharmacokinetic analysis (hausner et al., clinical pharmacokinetics) found?
A 2023 pharmacokinetic analysis (Hausner et al., Clinical Pharmacokinetics) found semaglutide reduced peak concentration of oral contraceptive hormones but did not significantly alter total drug exposure, meaning the pill-failure mechanism is not as clear-cut as the video implies.
What does the video say about women with pcos who had irregular?
Women with PCOS who had irregular or absent cycles due to obesity or insulin resistance may see ovulatory function return during GLP-1 therapy, a fertility change that can occur before significant weight loss is visible.
What does the video say about both semaglutide (ozempic, wegovy)?
Both semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) are not recommended for use during pregnancy based on animal reproductive toxicity data, and should be discontinued before planned conception.
What does the video say about the cortisol-depletion explanation offered in the video does not reflect?
The cortisol-depletion explanation offered in the video does not reflect established endocrinology and should not be used to understand or explain GLP-1-related fertility changes.
What does the video say about reproductive planning, including contraceptive method review?
Reproductive planning, including contraceptive method review and fertility counseling, should be part of any GLP-1 therapy intake for women of childbearing age, regardless of prior infertility history.
Sources & references
Citations extracted from our medical team's review. Click any citation to search PubMed.
Read More on This Topic
Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.
Not medical advice. This video was made by Primal Health + Wellness, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.